Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Blue Star Foods Provides Shareholder Update
November 27, 2023 09:00 ET
|
Blue Star Foods Corp.
Evaluating Several Strategic Acquisitive and Organic Growth Opportunities Miami, FL, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”)...
Revolution Medicines Completes Acquisition of EQRx
November 09, 2023 09:10 ET
|
Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 08, 2023 11:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for...
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 06, 2023 16:05 ET
|
Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 31, 2023 16:15 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 22, 2023 02:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
October 13, 2023 11:50 ET
|
Revolution Medicines, Inc.
Revolution Medicines reports encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors, at 2023 Triple Meeting
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
October 11, 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
October 04, 2023 16:05 ET
|
Revolution Medicines, Inc.
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....